Besides genome-wide significant associations with diseases of the circulatory system, variants in six drug target genes showed genome-wide significant associations with type 2 diabetes (NDUFA13, CILP2, PVRL2, VEGFA, APOC1, and LPL), five with Alzheimer’s disease (APOC1, PVR, PVRL2, APOE, and CEACAM16), four with asthma (SMARCA4, CETP, VEGFA, and ALDH1A2) and four with gout (APOA1, APOC3, APOA4, and APOA5). This evidence concerns the gene CEACAM16 and gout.